Teva Pharmaceutical Industries Limited (TEVA) analyst actions
Rating and price-target actions on TEVA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the TEVA overview →
4 measured TEVA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline | Press release | +0.41% | -0.84% | |
| S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive | Press release | -0.34% | -0.78% | |
| Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy | Press release | -0.77% | -1.05% | |
| Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma | Press release | -0.20% | -0.61% |
Keep exploring
More TEVA: earnings → · SEC filings → · TEVA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INC (ALDR) | 693 | -0.21% | 45% |
| DIGIRAD (DRAD) | 692 | 0.00% | 39% |
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.